{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:41:45Z","timestamp":1790743305274,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2011,1,1]],"date-time":"2011-01-01T00:00:00Z","timestamp":1293840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":1801,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/ki.2010.352","type":"journal-article","created":{"date-parts":[[2010,9,22]],"date-time":"2010-09-22T12:46:04Z","timestamp":1285159564000},"page":"112-119","source":"Crossref","is-referenced-by-count":140,"title":["Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism"],"prefix":"10.1016","volume":"79","author":[{"given":"Katherine","family":"Wesseling-Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata C.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Sahney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He-Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Elashoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"J\u00fcppner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/ki.2010.352_bb0010","first-page":"37","article-title":"Features of renal osteodystrophy in pediatric patients receiving regular peritoneal dialysis","volume":"9","author":"Salusky","year":"1989","journal-title":"Semin Nephrol"},{"key":"10.1038\/ki.2010.352_bb0015","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1359\/jbmr.2002.17.6.1102","article-title":"Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism","volume":"17","author":"De Beur","year":"2002","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2010.352_bb0020","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/j.1600-6143.2005.00914.x","article-title":"Early subclinical coronary artery calcification in young adults who were pediatric kidney transplant recipients","volume":"5","author":"Ishitani","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1038\/ki.2010.352_bb0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/ki.1987.176","article-title":"High-dose\u2019 calcitriol for control of renal osteodystrophy in children on CAPD","volume":"32","author":"Salusky","year":"1987","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0030","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ki.1994.380","article-title":"Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy","volume":"46","author":"Goodman","year":"1994","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0035","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1523-1755.1998.00724.x","article-title":"Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD","volume":"53","author":"Kuizon","year":"1998","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0040","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","article-title":"Arterial calcifications and bone histomorphometry in end-stage renal disease","volume":"15","author":"London","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.352_bb0045","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0050","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0055","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1681\/ASN.2004100885","article-title":"Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols","volume":"16","author":"Salusky","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.352_bb0060","first-page":"731","article-title":"Secondary hyperparathyroidism in chronic haemodialysis patients: a clinico-pathological study","volume":"20","author":"Mendes","year":"1983","journal-title":"Proc EDTA"},{"key":"10.1038\/ki.2010.352_bb0065","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.352_bb0070","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ndt\/gfn571","article-title":"Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.352_bb0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000408065","article-title":"Correlation of serum aluminum values with tissue aluminum concentration","volume":"38","author":"De Broe","year":"1984","journal-title":"Contrib Nephrol"},{"key":"10.1038\/ki.2010.352_bb0080","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1136\/jcp.37.2.136","article-title":"Detection and distribution of aluminium in bone","volume":"37","author":"Denton","year":"1984","journal-title":"J Clin Pathol"},{"key":"10.1038\/ki.2010.352_bb0085","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00467-009-1143-8","article-title":"Response of different PTH assays to therapy with sevelamer or CaCO3 and active vitamin D sterols","volume":"24","author":"Wesseling-Perry","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2010.352_bb0090","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/ndt\/gfg030","article-title":"Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone","volume":"18","author":"Upton","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1038\/ki.2010.352_bb0095","first-page":"s1","article-title":"KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Preventrion, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","volume":"76","author":"KDIGO Work Group","year":"2009","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/ki.1997.39","article-title":"Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism","volume":"51","author":"Tan","year":"1997","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0105","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1681\/ASN.V981427","article-title":"19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis","volume":"9","author":"Martin","year":"1998","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.352_bb0110","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.352_bb0115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0120","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1681\/ASN.2006101089","article-title":"Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients","volume":"19","author":"Ferreira","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.352_bb0125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","article-title":"An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism","volume":"69","author":"Malluche","year":"2008","journal-title":"Clin Nephrol"},{"key":"10.1038\/ki.2010.352_bb0130","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1046\/j.1525-139X.2002.00086.x","article-title":"Comparative review of the pharmacokinetics of vitamin D analogues","volume":"15","author":"Bailie","year":"2002","journal-title":"Semin Dial"},{"key":"10.1038\/ki.2010.352_bb0135","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0272-6386(12)80566-X","article-title":"Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients","volume":"16","author":"Salusky","year":"1990","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.352_bb0140","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2008-0326","article-title":"Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis","volume":"94","author":"Wesseling-Perry","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/ki.2010.352_bb0145","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","article-title":"Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease","volume":"45","author":"Pereira","year":"2009","journal-title":"Bone"},{"issue":"4 Suppl 3","key":"10.1038\/ki.2010.352_bb0150","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease","volume":"42","author":"National Kidney Foundation","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"4 Suppl 1","key":"10.1038\/ki.2010.352_bb0155","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease","volume":"46","author":"National Kidney Foundation","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1038\/ki.2010.352_bb0160","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-3476(82)80602-1","article-title":"25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity","volume":"100","author":"Langman","year":"1982","journal-title":"J Pediatr"},{"key":"10.1038\/ki.2010.352_bb0165","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1755.1998.00045.x","article-title":"Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration","volume":"54","author":"Salusky","year":"1998","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0170","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1046\/j.1523-1755.2003.00328.x","article-title":"Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers","volume":"64","author":"Larsson","year":"2003","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0175","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/j.1523-1755.2005.00184.x","article-title":"Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients","volume":"67","author":"Nakanishi","year":"2005","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0180","series-title":"Clin J Am Soc Nephrol","article-title":"Early Control of PTH and FGF23 in Normophosphatemic CKD Patients: A New Target in CKD-MBD Therapy?","author":"Oliveira","year":"2009"},{"key":"10.1038\/ki.2010.352_bb0185","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Ther Apher Dial"},{"key":"10.1038\/ki.2010.352_bb0190","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.352_bb0195","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsbmb.2006.12.054","article-title":"1,25-Dihydroxyvitamin D3\/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism","volume":"103","author":"Barthel","year":"2007","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1038\/ki.2010.352_bb0200","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1359\/JBMR.050718","article-title":"Fibroblast growth factor-23 is regulated by 1alpha,25-dihydroxyvitamin D","volume":"20","author":"Collins","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1038\/ki.2010.352_bb0205","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bone.2005.03.002","article-title":"Genetic dissection of phosphate- and vitamin D-mediated regulation of circulating Fgf23 concentrations","volume":"36","author":"Yu","year":"2005","journal-title":"Bone"},{"key":"10.1038\/ki.2010.352_bb0210","doi-asserted-by":"crossref","first-page":"G1036","DOI":"10.1152\/ajpgi.00243.2005","article-title":"1alpha,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport","volume":"289","author":"Kolek","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1038\/ki.2010.352_bb0215","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1038\/ki.2010.352_bb0220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.352_bb0225","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","article-title":"Mortality risk among hemodialysis patients receiving different vitamin D analogs","volume":"70","author":"Tentori","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0230","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Gutierrez","year":"2009","journal-title":"Circulation"},{"key":"10.1038\/ki.2010.352_bb0235","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ki.2009.246","article-title":"A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease","volume":"76","author":"Isakova","year":"2009","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0240","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/clinchem\/33.8.1364","article-title":"Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia","volume":"33","author":"Nussbaum","year":"1987","journal-title":"Clin Chem"},{"key":"10.1038\/ki.2010.352_bb0245","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1007\/s00467-003-1298-7","article-title":"Sevelamer hydrochloride: an effective phosphate binder in dialyzed children","volume":"18","author":"Mahdavi","year":"2003","journal-title":"Pediatr Nephrol"},{"key":"10.1038\/ki.2010.352_bb0250","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/clinchem\/39.3.529","article-title":"Determination of vitamin D status by radioimmunoassay with an 125I-labeled tracer","volume":"39","author":"Hollis","year":"1993","journal-title":"Clin Chem"},{"key":"10.1038\/ki.2010.352_bb0255","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","article-title":"Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"69","author":"Moe","year":"2006","journal-title":"Kidney Int"},{"key":"10.1038\/ki.2010.352_bb0260","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJM199102213240804","article-title":"Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease","volume":"324","author":"Salusky","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1038\/ki.2010.352_bb0265","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1046\/j.1523-1755.1998.00866.x","article-title":"Bone disease in children and adolescents undergoing successful renal transplantation","volume":"53","author":"Sanchez","year":"1998","journal-title":"Kidney Int"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815546784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815546784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T12:17:42Z","timestamp":1636546662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815546784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["S0085253815546784"],"URL":"https:\/\/doi.org\/10.1038\/ki.2010.352","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2011,1]]}}}